Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

NARecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 1, 2010

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cirrhosis
Interventions
DRUG

carvedilol

Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.

DRUG

Placebo

The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.

Trial Locations (1)

Unknown

RECRUITING

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT01212250 - Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis | Biotech Hunter | Biotech Hunter